Vidiia, Ellison's Brain Cancer Treatment Development Progressing Smoothly... "Phase 3 Clinical Trials to be Conducted by Next Year"

[Asia Economy Reporter Hyunseok Yoo] Vidia announced on the 12th that Ellison's brain cancer treatment drug ‘DBD (Dibromodulcitol)’, which is under development in the United States, is expected to enter Phase 3 clinical trials by the first half of next year at the latest.

DBD is an oral chemotherapy drug being developed to treat glioblastoma, which is considered the most malignant type of brain tumor. DBD was originally developed by the National Cancer Institute (NCI). It has secured a large-scale safety database through multiple Phase 1 and Phase 2 clinical trials, and its efficacy has been confirmed in both solid tumors and hematologic cancers.

Additionally, as an orally administered drug, it is easier to apply compared to intravenous infusion therapy, and it has been shown to be effective in both newly diagnosed brain tumor patients and those resistant to standard chemotherapy.

A Vidia official stated, “Ellison has executives with extensive new drug development experience and a world-class scientific advisory board that possesses the expertise necessary for efficient product development,” adding, “We will minimize development and regulatory risks through scientific knowledge based on existing commercialized anticancer drugs and data secured from numerous clinical trials.”

He continued, “As the largest shareholder, Vidia will establish a strategic partnership with Ellison to ensure that Ellison can become a pharmaceutical company that offers new hope to patients with rare cancers such as pancreatic cancer, lung cancer, and brain tumors.”

In addition to the brain cancer treatment drug DBD, Ellison is currently conducting clinical trials on three clinical pipeline drugs targeting three indications. The pancreatic cancer single second-line treatment ‘Glufosfamide’ is undergoing Phase 3 clinical trials with the FDA. The inhaled lung cancer and pediatric osteosarcoma treatment (ILC) has submitted a Phase 2/3 clinical trial plan to the FDA and is awaiting approval.